I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $261.78M

Company

Location

Date

Amt. (M)

Details

Acorda Therapeutics Inc.

Hawthorne, N.Y.

3/9

$6

Acorda raised $6M in the second closing of a private venture financing round; the round brought in $33.7M in January

Alchemia Inc.

Redwood City, Calif.

3/29

$8.2

Investors included Start-up Australia, Medica Holdings, Biotech Capital and Rothschild Bioscience Australia

Ardais Corp.

Lexington, Mass.

3/19

$33.5

Ardais raised $33.5M in a private placement; participants included EGS Healthcare Capital Partners, The Kaufmann Fund, Pequot Private Equity Fund, The CIT Group, Radius Venture Partners, Silicon Valley Partners, Advanced Technology Ventures, Advent Health Care and Life Sciences, Bessemer Venture Partners and BioVentures

CancerVax Corp.

Santa Monica, Calif.

3/6

$30

CancerVax raised $30M in initial financing led by Forward Ventures; other investors included Vector Fund Management LP, Amerindo Investment Advisors Inc., Athenian Venture Partners, and a group of other institutional and private investors

Caprion Pharmaceuticals Inc.

Montreal

3/13

US$4.1

Caprion completed a second closing of its financing, which has raised a total of $37.5M; Ventures West and Fidelity Management Research Co. led the financing, which was manged by Yorkton Securities Co.

Cellzome GmbH

Heidelberg, Germany

3/1

$31

Cellzome raised $31M in its second-round financing led by Index Ventures; other investors were Sofinnova Ventures, Schroders Investment Management Ltd., Atlas Ventures, Advent International and Heidelberg Innovation BioScience Venture

Chromagen Inc.

San Diego

3/23

$15

Chromagen raised $15M in its sixth round of financing; Dain Rauscher Wessels acted as the placement agent and adviser; Zesiger Capital Group led the round, which included Essex Capital, S.A.C. Capital Associates, DRW Venture Partners, United Capital, JAFCO and Nippon Venture Capital

Icagen Inc.

Research Triangle Park, N.C.

3/27

$22.8

Icagen raised $22.8M; investors included the China Development Industrial Bank, Quintiles Transnational Corp., Abbott Laboratories, New Medical Technologies, Alta Partners and Venrock Associates

LumiCyte Inc.

Fremont, Calif.

3/30

$20

LumiCyte raised $20M in its Series B round of financing led by Tullis-Dickerson & Co.; investors included OrbiMed Advisors LLC and the Redleaf Group

Matrix Therapeutics Ltd.

Nottingham, UK

3/21**

#2 (US$2.85)

Matrix raised US$2.85M in a first-round funding, which included lead investor Technomark Medical Ventures

NatImmune A/S

Copenhagen, Denmark

3/22

$7.5

Investors included Dansk Innovationsinvestering, Novo A/S, Lonmodtagernes Dyrtidsfond, Kommunernes Pensionsforsikring and Vaekstfonden

NeuroMed Technologies Inc.

Vancouver, British Columbia

3/27

C$3.8 (US$2.4)

NeuroMed increased its second round of financing, announced in January, by US$2.4M, bringing the total for the round to just under C$21M

Oasis Biosciences Inc.

San Diego

3/29

$7

Oasis raised $7M in a Series A financing with lead investor GeneScan-Europe AG; Artisan Ventures Ltd. also participated

Pharmagenesis Inc.

Palo Alto, Calif.

3/6

ND

Pharmagenesis completed a funding round for an undisclosed amount from a group of investors that included Biomerieux-Pierre Fabre, The Dassault Group, AXA and an unnamed Hong Kong investment group

Pharmasset Ltd.

Bridgetown, Barbados

3/14

$7.4

Pharmasset raised $7.4M in a private round of equity financing made by TVM Techno Venture Management

ProdiGene Inc.

College Station, Texas

3/13

$9

ProdiGene raised $9M through the private placement of preferred stock; StaufferSeeds Inc. led the financing round

Santarus Inc.

San Diego

3/8

$33.2

Santarus raised $33.2M in a Series C financing that included the following investors: Domain Associates LLC, J.P. Morgan Partners and Advent Venture Partners, as well as St. Paul Venture Capital, Windamere Capital Ventures, Fog City Fund and Windamere LLC

SpiroGen Ltd.

Bryde, Isle of Wight, UK

3/15

#1 (US$1.4)

SpiroGen raised US$1.4M in a financing with Cambridge Research BioVentures Ltd. as lead investor

Synt:em

Paris

3/7

EUR22 (US$20.43)

Synt:em raised US$20.43M in a financing that included the following investors: Apax Partners & Cie, Banexi Ventures, Healthcap, Lombard Odier & Cie, BankInvest, Rendex, Private Equity Holding, Medicis and Mercure Biotech

II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $3.05M

Company (Symbol)#*

Partner (Symbol; Country)

Amt. (M)

Triggering Event

Details (Date)

Exelixis Inc. (EXEL)

Bayer AG (Germany)

ND

Milestone payment

Exelixis received an undisclosed milestone payment for delivering several novel insecticide targets for assay development and high-throughput screening (3/23)

GPC Biotech AG (Germany; OTC BB:GPCBF)

Byk Gulden (unit of Altana AG; Germany)

ND

Milestone payments

GPC Biotech achieved two milestones involving clustering the mode of action of known antibacterial compounds and differentiating between their molecular mechanisms, as well as analyzing and characterizing lead drug candidates against Helicobacter pylori infections (3/30)

Hematech LLC*

Kirin Brewery Co. Ltd. (Japan)

ND

Milestone payment

Hematech received a milestone payment from its collaboration on the production of TransChromo animals that express human polyclonal antibodies (3/5)

Kinexus Bioinformatics Corp. (Canada)*

BIRC Corp. (Canada)

$0.25

Tranche investment

Kinexus received a second tranche investment from BIRC of $250,000 (3/26)

Matrix Therapeutics Ltd. (UK)*

Technomark Medical Ventures (UK), Generics Asset Management, Interlkea Finance SA and Sopartec

#2 (US$2.8)

Syndicated investment

Matrix received a US$2.8M syndicated investment from Technomark, Generics Asset, Interlkea and Sopartec (3/19)

MorphoSys AG (Germany; Neuer Markt:MOR)

F. Hoffmann-La Roche Ltd. (Switzerland)

ND

Milestone payment

MorphoSys achieved its second milestone by delivering a series of HuCAL antibodies targeting an unspecified Roche antigen (3/21)

Paradigm Genetics Inc. (PDGM)

Monsanto Co.

ND

Milestone payment

Paradigm exceeded its fourth milestone in its commercial partnership for discovering gene function of Monsanto genes, triggering an undisclosed milestone payment (3/6)

XTL Biopharmaceuticals Ltd. (Israel; LSE:XTL)

Undisclosed corporate partner

ND

Milestone payments

XTL received multiple milestone payments based on products advancing into clinical testing to treat hepatitis C virus (3/19)

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

LSE = London Stock Exchange; OTC BB = Over The Counter Bulletin Board

*Denotes privately held company. ND = not disclosed

No Comments